| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
SAN DIEGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmace...
Jones Trading analyst Catherine Novack initiates coverage on Aardvark Therapeutics (NASDAQ:AARD) with a Buy rating and annou...
Stifel analyst James Condulis initiates coverage on Aardvark Therapeutics (NASDAQ: AARD) with a Buy rating and announces Pri...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aardvark Therapeutics (NASDAQ:AARD) with a Buy and maintains $...
B of A Securities analyst Tim Anderson maintains Aardvark Therapeutics (NASDAQ:AARD) with a Buy and lowers the price target ...
RBC Capital analyst Brian Abrahams maintains Aardvark Therapeutics (NASDAQ:AARD) with a Outperform and lowers the price targ...
Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimate ...
